Home >> Professional Blog
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced its results for the quarter ended March 31, 2013.
Highlights of First Quarter 2013 Results include:
* Revenue exceeded forecast for fifth consecutive quarter
* Revenue more than triples over first quarter of 2012
* Fifth consecutive quarter of positive Adjusted EBITDA
* Gross Margins improved by 10 percent over Q1 of prior year
* Company reiterates 2013 guidance
